Cidara Therapeutics Inc

Cidara Therapeutics — Corporate Update (June 2025)

12 slides from Cidara Therapeutics's corporate update, Jun 23, 2025

  1. Slide 1: NAVIGATE Ph 2B

    NASDAQ: CDTX NAVIGATE Ph 2B June 23, 2025 JUNE 2025

  2. Slide 2: Forward-looking Statements

    2 Forward-looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “estimate,” “plan”, “anticipate,” “expect,” “potential,” “could,” “project,” and similar expressions (including the negati

  3. Slide 3: Agenda

    3 Agenda Topic Discussant Introduction Jeff Stein, PhD NAVIGATE Phase 2b Trial Data Cut Nicole Davarpanah, MD, JD Q&A Discussion Cidara Management

  4. Slide 4: DFCs: A Novel Drug Class

    4 DFCs: A Novel Drug Class CD388 is a Drug-Fc-Conjugate (DFC) that arrays multiple copies of zanamivir, the active ingredient of FDA-approved influenza drug Relenza®, on a clinically validated human antibody fragment engineered for extended half-life Our Innovation The multivalent presentation of za

  5. Slide 5: Executive Summary: The NAVIGATE Study Met Primary and All Secondary Endpoints

    5 Executive Summary The NAVIGATE Study Met Primary and All Secondary Endpoints NAVIGATE Ph 2B Trial Abbreviations: Ph, phase. • The primary endpoint of Prevention Efficacy (PE) of protocol-defined Influenza-like illness (ILI) events at 24 weeks was met with statistical significance at each dose grou

  6. Slide 6: CD388 NAVIGATE Trial Design

    6 CD388 NAVIGATE Trial Design* A Double-blind RCT of CD388 for Influenza Prophylaxis Clinical: Ph 2B Trial Blinded, randomized, controlled trial of CD388 in 3 doses vs placebo as a single SQ administration to assess efficacy and safety of CD388 in prevention of influenza in subjects not at risk for

  7. Slide 7: Primary Endpoint Met With Statistical Significance in Each Dose Group

    7 Primary Endpoint Met With Statistical Significance in Each Dose Group NAVIGATE Ph 2B Efficacy Analyses CD388 Primary Endpoint** 150 mg N=1,175* n (%) 300 mg N=1,192* n (%) 450 mg N=1,187* n (%) Placebo N=1172* n (%) Number of Participants Protocol-Defined ILI 1 14 (1.2) 13 (1.1) 8 (0.7) 33 (2.8) P

  8. Slide 8: Key Secondary Endpoints Demonstrated Statistical Significance at All Specified Temperatures

    8 Key Secondary Endpoints Demonstrated Statistical Significance at All Specified Temperatures NAVIGATE Ph 2B Efficacy Analyses Abbreviations: ILI, influenza like illness; CI, confidence interval: PCR, polymerase chain reaction. 1. CDC definition: ILI event defined as central laboratory-confirmed RT-

  9. Slide 9: Safety Summary: No Safety Signals

    9 Safety Summary: No Safety Signals • Safety and tolerability data were similar in all arms with no safety signals observed • Treatment-emergent adverse events (TEAEs) showed no dose-dependent pattern between CD388 and placebo groups • Majority of TEAEs were unrelated to study drug and Grade 1/Grade

  10. Slide 10: Participant Demographics: Balanced Across All Arms

    10 Participant Demographics: Balanced Across All Arms NAVIGATE Ph 2B Trial CD388 150 mg N=1,268 300 mg N=1,268 450 mg N=1,268 Placebo N=1,267 Age 18 - <40 yrs (%) 649 (51.2) 640 (50.5) 646 (50.9) 620 (48.9) 40 - <64 yrs* (%) 619 (48.8) 628 (49.5) 622 (49.1) 647 (51.1) Mean (SD) 39.7 (12.67) 39.6 (12

  11. Slide 11: Next Steps

    11 Next Steps • Full primary analysis details will be submitted to upcoming scientific conferences in 2025 • Dose for Phase 3 will be selected after full PK data is assessed • Drug supply for any dose is available to begin Phase 3 • End of Phase 2 FDA meeting request has been submitted to continue d

  12. Slide 12: Thank You

    Thank You cidara.com

Cidara Therapeutics — Corporate Update (June 2025) on 6ix